focus -WSS

focus

author：entertainment 2025-09-30 14:57:53 - browse：44

U.S. Sen. Bernie Sanders sets his hands on two chairs as two people set up a board displaying a "price of drugs" chart behind him — politics coverage from STAT — Sen. Bernie Sanders has used his leadership of a Senate committee to pressure drugmakers to lower their prices. Kevin Dietsch/Getty Images

WASHINGTON — Bernie Sanders is figuring out just how far bullying drugmakers can take him.

For more than a year, Sanders has used his perch atop the Senate health committee to haul the CEOs of pharmaceutical companies that make insulin, vaccines, and more before the panel with progressively more ambitious demands related to their pricing. After a few victories he’s claimed — experts say some credit is deserved, but the full story is a bit more complicated — he’s now progressed to demanding that Novo Nordisk cut its price for its novel, wildly popular diabetes and weight-loss drugs.

Sanders (I-Vt.) is testing the limits of the powers of a Senate chairman with little hope of advancing his policy agenda legislatively. He’s threatened subpoenas, held a prominent nominee hostage, and initiated investigations to get his way. It’s a sharp departure from the modest, bipartisan ambitions that more disciplined, discreet leaders of the committee have taken in years past, and sets the bar for how much can be accomplished using the full extent of the bully pulpit.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Boston Scientific acquires urology company Axonics for $3.7 billion

WSS

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Boston Scientific acquires urology company Axonics for $3.7 billion

Latest bird flu infection made farmworker sicker than earlier cases

Scientists successfully use ultrasound imaging to map brain activity

Allen Institute goes after foundational questions, CEO Costa says

leisure time

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Wikipedia

Wildfire smoke exposes gaps in outdoor worker protections

Heat waves linked to early deliveries, preterm births in new study

In Memoriam: Notable people who died in 2023

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Guidelines to prevent youth baseball injuries need more muscle

Latest bird flu infection made farmworker sicker than earlier cases

Jerome Adams on the need for new antivirals for Covid

Life science postdocs should get big pay hike, NIH panel says

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Boston Scientific acquires urology company Axonics for $3.7 billion

leisure time

Biohaven protein

Arena BioWorks launches in Cambridge to speed drug discovery

Medicare Advantage overpayments discussion gets experts fired up

Childbirth

Merck to acquire Harpoon Therapeutics for $680 million

Focused ultrasound for uterine fibroids: an uphill battle

focus

Wikipedia

leisure time

hotspot